The hits keep coming.
Journal of Hand and Microsurgery
https://www.sciencedirect.com/science/article/abs/pii/S0974322724001157
We are currently increasing pricing annually. But most Interesting is how much we will be able to increase our prices once fully established.
FesObjective This study aims to compare outcomes between Novosorb Biodegradable Temporizing Matrix (BTM) and Integra collagen-chondroitin silicone for upper-extremity wound reconstruction.
Methods This retrospective study analyzed adult patients who underwent wound reconstruction with either BTM or Integra at our institution between 2015 and 2020.
Results Forty-eight patients were included: 31 (64.6%) BTM and 17 (35.4%) Integra. Mean age was 44.0 (range: 18–68) years. Age, race, sex, smoking, comorbidities, and defect size were similar between groups. Wound etiologies included 12 (25.0%) burn, 22 (45.8%) trauma, and others. Median template size was 133 cm2 for BTM and 104 cm2 for Integra (p = 0.526). Skin grafting was performed after 14 (45.2%) and 14 (82.4%) wounds treated with BTM and Integra, respectively (p = 0.028). Template complications of infection and dehiscence were comparable. Skin-graft complications occurred in five (35.7%) and three (21.4%) wounds in BTM and Integra, respectively (p = 0.031). Skin-graft failure rates were comparable (p = 0.121). Mean number of secondary procedures required after template placement was higher in the Integra group (BTM, 1.0; Integra, 1.9; p = 0.090). Final healing was achieved in 17 (54.8%) BTM and 11 (64.7%) Integra wounds (p = 0.694). Median time to healing was 4.1 months after BTM and 2.6 months after Integra placement (p = 0.014).
Conclusion Compared with Integra, BTM achieved comparable wound healing and complication rates. Fewer secondary procedures and skin grafts were observed in BTM wounds, likely as a result of the coronavirus disease 2019 pandemic. At our institution, 100 cm2 of product costs $850 for BTM and $3,150 for Integra, suggesting BTM as an economical alternative to fulfill the high functional and aesthetic requirements of upper-extremity wounds.
- Forums
- ASX - By Stock
- PNV
- The Clinicians Speak
The Clinicians Speak, page-963
-
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PNV (ASX) to my watchlist
|
|||||
Last
$2.35 |
Change
0.020(0.86%) |
Mkt cap ! $1.622B |
Open | High | Low | Value | Volume |
$2.37 | $2.40 | $2.34 | $2.822M | 1.196M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 13436 | $2.34 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.36 | 11159 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3332 | 2.340 |
5 | 9998 | 2.330 |
3 | 8423 | 2.320 |
3 | 9362 | 2.310 |
9 | 19517 | 2.300 |
Price($) | Vol. | No. |
---|---|---|
2.360 | 11159 | 4 |
2.370 | 10635 | 3 |
2.380 | 2207 | 1 |
2.390 | 2207 | 1 |
2.400 | 26046 | 5 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |